Shingrix™ (zoster vaccine recombinant, adjuvanted) – New drug approval
October 20, 2017 – GlaxoSmithKline announced the FDA approval of Shingrix (zoster vaccine recombinant, adjuvanted), for the prevention of herpes zoster (shingles) in adults aged 50 years and older.
Download PDF
